Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with …
In addition to the contribution of cancer cells, the solid tumor microenvironment (TME) has a
critical role in determining tumor expansion, antitumor immunity, and the response to …
critical role in determining tumor expansion, antitumor immunity, and the response to …
Barriers and opportunities in pancreatic cancer immunotherapy
Y Ju, D Xu, M Liao, Y Sun, W Bao, F Yao… - NPJ Precision …, 2024 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) presents a fatal clinical challenge characterized
by a dismal 5-year overall survival rate, primarily due to the lack of early diagnosis and …
by a dismal 5-year overall survival rate, primarily due to the lack of early diagnosis and …
Synthetic cytokine circuits that drive T cells into immune-excluded tumors
Chimeric antigen receptor (CAR) T cells are ineffective against solid tumors with
immunosuppressive microenvironments. To overcome suppression, we engineered circuits …
immunosuppressive microenvironments. To overcome suppression, we engineered circuits …
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions
Cancer-associated fibroblasts (CAFs) are a common cell in the tumour microenvironment
with diverse tumour-promoting functions. Their presence in tumours is commonly associated …
with diverse tumour-promoting functions. Their presence in tumours is commonly associated …
Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer
H Araki, H Tazawa, N Kanaya, Y Kajiwara… - Molecular Therapy …, 2022 - cell.com
Immune checkpoint inhibitors, including anti-programmed cell death 1 (PD-1) antibody,
provide improved clinical outcome in certain cancers. However, pancreatic ductal …
provide improved clinical outcome in certain cancers. However, pancreatic ductal …
TGFβ signaling in the pancreatic tumor microenvironment
DR Principe, KE Timbers, LG Atia, RM Koch, A Rana - Cancers, 2021 - mdpi.com
Simple Summary There is currently no effective treatment for patients with advanced
pancreatic ductal adenocarcinoma (PDAC). Transforming Growth Factor β (TGFβ) signaling …
pancreatic ductal adenocarcinoma (PDAC). Transforming Growth Factor β (TGFβ) signaling …
[HTML][HTML] TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
M Perez-Penco, SE Weis-Banke, A Schina… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is associated with very poor
survival, making it the third and fourth leading cause of all cancer-related deaths in the USA …
survival, making it the third and fourth leading cause of all cancer-related deaths in the USA …
Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing
Pancreatic ductal adenocarcinoma (PDA) is an inherently immune cell deprived tumor,
characterized by desmoplastic stroma and suppressive immune cells. Here we …
characterized by desmoplastic stroma and suppressive immune cells. Here we …
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma
S Ravindranathan, T Passang, JM Li, S Wang… - Nature …, 2022 - nature.com
A paucity of effector T cells within tumors renders pancreatic ductal adenocarcinoma (PDAC)
resistant to immune checkpoint therapies. While several under-development approaches …
resistant to immune checkpoint therapies. While several under-development approaches …
Intracellular Salmonella delivery of an exogenous immunization antigen refocuses CD8 T cells against cancer cells, eliminates pancreatic tumors and forms antitumor …
V Raman, LM Howell, SMK Bloom, CL Hall… - Frontiers in …, 2023 - frontiersin.org
Introduction Immunotherapies have shown great promise, but are not effective for all tumors
types and are effective in less than 3% of patients with pancreatic ductal adenocarcinomas …
types and are effective in less than 3% of patients with pancreatic ductal adenocarcinomas …